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At a Glance Commentary: Scientific Knowledge on the Subject 
Primary Ciliary Dyskinesia is a genetically heterogeneous chronic condition.  Early diagnosis 
is key to attenuating disease progression by implementation of appropriate medical 
management.  Currently diagnosis requires expensive and complex equipment 
 
What This Study Adds to the Field 
This study validates the clinical use of a panel of commercially available antibodies to 
diagnose Primary Ciliary Dyskinesia by immunofluorescence, a simpler, more widely 
available, cost effective alternative to current confirmatory diagnostic tests. 
Immunofluorescence is a useful diagnostic test for PCD, reduces the need for repeat biopsies, 
and improves turnaround time without compromising diagnostic accuracy. 
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ABSTRACT 
Rationale The standard approach to diagnosis of primary ciliary dyskinesia (PCD) in the UK 
consists of assessing ciliary function by high-speed-microscopy and ultrastructure by election 
microscopy, but equipment and expertise is not widely available internationally. The 
identification of bi-allelic disease causing mutations is also diagnostic, but many disease 
causing genes are unknown, and testing is not widely available outside the USA. Fluorescent 
antibodies to ciliary proteins are used to validate research genetic studies, but diagnostic 
utility in this disease has not been systematically evaluated. 
 
Objectives Determine utility of a panel of six fluorescent labelled antibodies as a diagnostic 
tool for PCD. 
 
Methods Immunofluorescent labelling of nasal brushings from a discovery cohort of 35 
patients diagnosed with PCD by ciliary ultrastructure, and a diagnostic accuracy cohort of 
386 patients referred with symptoms suggestive of disease. The results were compared to 
diagnostic outcome. 
 
Measurements and Main Results Immunofluorescence correctly identified mislocalised or 
absent staining in 100% of the discovery cohort. In the diagnostic cohort 
immunofluorescence successfully identified 22 of 25 patients with PCD and normal staining 
in all 252 in whom PCD was considered highly unlikely. Immunofluorescence additionally 
provided a result in 55% (39) of cases which were previously inconclusive. 
Immunofluorescence results were available within 14 days, costing $187 per sample 
compared to electron microscopy (27 days, cost $1452). 
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Conclusions Immunofluorescence is a highly specific diagnostic test for PCD, and improves 
the speed and availability of diagnostic testing, however, sensitivity is limited and 
immunofluorescence is not suitable as a stand-alone test. 
Abstract word count: 250 
Key words: Cilia, Electron microscopy, Antibody 
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INTRODUCTION 
 
Primary Ciliary Dyskinesia (PCD) affects approximately 1 in 15,000 of the population.  Its 
manifestations are caused by defective ciliary beating and reduced mucociliary clearance. 
Diagnosis is frequently delayed, and delay is associated with significant impairment of lung 
function. Diagnostic delay is related to two factors: the non-specificity of symptoms (cough, 
rhinitis) and the lack of an easy and widely available diagnostic test for the condition [1] 
 
The diagnostic pathway for PCD typically includes measurement of nasal nitric oxide and 
nasal brush biopsy for light and electron microscopy. Light microscopic assessment of ciliary 
function on cells ex-vivo is by high speed video analysis of the frequency and pattern 
(waveform) of cilia movement. Electron microscopy allows visualisation of the ultrastructure 
of cilia and can often provide a definitive diagnosis [1]. All these tests require sophisticated 
equipment and considerable expertise, and in consequence are only available in very few 
centres. Genetic testing for PCD is also increasingly used, but there are at least 200 potential 
motile cilia genes which are widely scattered through the human genome. To date, more than 
30 disease-associated mutations have been identified, which are estimated to account for 60-
65% of known cases [1,2,3]. 
 
Immunofluorescence allows indirect imaging of target proteins by fluorescent or confocal 
microscopy using specific antibodies with fluorescent tags.  The use of different tags for 
double labelling allows the co-localisation of proteins to be determined. Immunofluorescence 
for the diagnosis of PCD was first described in 2005 and was subsequently recommended in 
the ERS expert consensus statement for diagnosis and treatment of PCD [4,5]. Despite this 
recommendation limited availability of validated antibodies and lack of evidence for the 
Page 6 of 39 AJRCCM Articles in Press. Published on 15-February-2017 as 10.1164/rccm.201607-1351OC 
 Copyright © 2017 by the American Thoracic Society 
 Page 4 of 27 
 
diagnostic accuracy of the technique has limited its use.  Immunofluorescence has been used 
extensively in PCD research in confirming protein absence due to genetic mutations. A 
number of antibodies to proteins defective in PCD have been developed and validated. These 
include DNAH5 (an outer dynein arm heavy chain) [4,6], DNALI1 (an inner dynein arm light 
chain)[6,7], GAS8 (a component of the nexin -dynein regulatory complex) [7] and RSPH4A, 
RSPH9 and RSPH1 (components of the radial spoke)[8]. These antibodies represent markers 
of the four key ultrastructural abnormalities in PCD.  Detected by electron microscopy these 
defects are the end products of multiple gene defects (Table 1 and Figure 1). By 
immunofluorescence the absence or mislocation of a single protein can allow the effects of 
mutations in multiple genes to be detected (Table 1). We hypothesised that 
immunofluorescence using a panel of antibodies would be a useful diagnostic test for PCD, 
and aimed to assess this in the clinic in a large cohort of patients with possible PCD referred 
for diagnostic testing. 
 
METHODS 
Subjects 
Discovery cohort- Nasal brushings were analysed from a cohort of 35 patients with a known 
PCD ultrastructural defect (thus excluding 30% of PCD patients with normal 
ultrastructure)[9]. 
Diagnostic accuracy cohort- Nasal brushings were analysed from 386 patients sequentially 
referred to the Royal Brompton Hospital for PCD diagnosis.  Referrals were due to symptoms 
suggestive of PCD such as situs inversus, neonatal respiratory distress, bronchiectasis, 
recurrent chest infections, rhinosinusitis and otitis media (listed in OLS supplementary table 
1). 
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Diagnosis of PCD 
All patients underwent a standardised diagnostic protocol regularly audited across 3 UK  
PCD centres which form a national specialised service (Leicester Royal Infirmary, 
Southampton Hospital and Royal Brompton Hospital) [1].  This consisted of six assessments 
as follows: 
  
1. Assessment for symptoms suggestive of PCD (n= 378/386; 8 external samples had a 
limited clinical history).  
2. Nasal Nitric Oxide measurement – In children >4 years. Two readings from each nostril 
were taken during a breath hold manoeuvre using a chemiluminescent analyser LR2000 
(Logan Research, Rochester, UK) [10] (n= 129/386) 
3. High speed video microscopy for cilia beat frequency and ciliary beat pattern measured at 
37ºC using a 100x objective [11] (n=386/386) 
4. Quantitative transmission electron microscopy of ciliary ultrastructure [12] (n=208/386) 
5. Air liquid interface culture of difficult samples and repeat light and electron microscopy 
[13] (n=115/386) 
6. Genotyping from blood sample in patients with likely PCD based on positive results from 
at least two of the other investigations (n=16/386) 
 
In the absence of an established gold standard, a diagnosis of PCD was made following a 
review of clinical and laboratory findings in a monthly multidisciplinary meeting led by a 
consultant clinician with expertise in PCD.  Further details of diagnostic decision making 
pathways are described in the online supplement.  
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Experimental methods 
Methodological details are provided in the online data supplement [4]. All slides were double 
labelled with acetylated alpha tubulin (T7451, Sigma Aldrich) in order to visualise cilia. 
Antibodies of interest were used in a two step protocol. All nasal brushings were assessed for 
Panel 1: DNAH5 (HPA037470), DNALI1 (HPA053129), RSPH4A (HPA031196). A second 
round of antibodies were used in selected cases: Panel 2: RSPH9 (HPA031703), RSPH1 
(HPA017382) or GAS8 (HPA041311) 
 
Slides were scanned under a fluorescent microscope for ciliated cells at x40 magnification to 
identify acetylated tubulin. In each ciliated cell, the co-localised ciliary protein of interest was 
assessed in a second channel. If there was visual co-localisation of the antibody label with 
acetylated tubulin, the target protein was considered present. If more than seven of ten 
ciliated cells were clearly labelled with the target protein antibody the sample was considered 
normal for that protein.  PCD was defined as diagnosed when on duplicate slides all ciliated 
cells observed had absent staining of the target protein from the axoneme or staining 
consistently isolated to the distal or proximal portion of the cilia. Insufficient (<10 cells 
observed) and inconclusive slides were repeated. If the first slide was insufficient or 
inconclusive but the second assessment was normal the result was considered normal (n=71). 
 
Statistical methods 
The number of patient results reviewed was based on a 10% prevalence of PCD in the 
population tested. Power calculations predicted 271 patients with a confirmed diagnosis of 
‘PCD’ or ‘PCD highly unlikely’ would be required for 95% confidence. Results were 
analysed in graph pad prism 5 and a p value <0.05 was considered significant.  
Page 9 of 39  AJRCCM Articles in Press. Published on 15-February-2017 as 10.1164/rccm.201607-1351OC 
 Copyright © 2017 by the American Thoracic Society 
 Page 7 of 27 
 
 
ETHICS 
This study was conducted according to the recommendations of the Declaration of Helsinki.  
The protocol was approved by ethical review committee and written consent was obtained 
from subjects or their parent/guardian.  
 
RESULTS 
Immunofluorescence can be used to confirm a diagnosis of PCD 
Antibodies were tested on nasal brushings from a discovery cohort of 35 patients with PCD 
with a confirmed ultrastructural ciliary defect.  Results shown in Table 2 demonstrated a 
complete agreement between the absence of structure by electron microscopy and absence of 
associated protein by immunofluorescence. 
 
Diagnostic accuracy of immunofluorescence in the diagnostic accuracy cohort 
The immunofluorescence technique successfully demonstrated an absence of target proteins 
from the axoneme in 22 of 25 patients with a diagnosis of PCD as defined above. Normal 
results were obtained in all 252 patients who were considered highly unlikely to have PCD.  
 
Figure 2 shows an example of immunofluorescent staining of ciliated epithelial cells from 
two patients who were ‘PCD-positive’ and a patient who was ‘PCD-highly unlikely’.   
Results of the diagnostic tests and immunofluorescence tests are shown in Tables 3 and 4. 
Immunofluorescence identified PCD protein defects in all patients who had an identifiable 
ultrastructural defect by electron microscopy.  The number of patients in which PCD was 
confirmed by immunofluorescence  was the same as that of electron microscopy. 
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Three patients who were diagnosed as ‘PCD- positive’ were not identified using the 
immunofluorescence protocol and were examined in closer detail.  Genetic tests in two 
patients showed mutations in DNAH11. Both patients had a beat pattern consistent with this 
defect (hyperfrequent, stiff and static) on more than one biopsy and nasal NO <77nl/min. One 
patient had consanguineous parents and was homozygous for a nonsense mutation 
(c.3380G>A , p.Trp1127*) the other had heterozygous nonsense changes (c.5506C>T , 
p.Arg1836* and c.5636T>A p.Leu1879*).  The third individual was also from 
consanguineous parentage and was homozygous for a frame shift mutation in the HYDIN 
gene (c.2196dupT, p.Y372fs). The cilia ultrastructure in these three patients was considered 
normal by standard electron microscopy. Electron tomography from the patient with the 
HYDIN mutations showed absence of the c2b central pair projection [14]. 
 
Insufficient and inconclusive samples 
 
Immunofluorescence as part of the diagnostic pathway could reduce the requirement for 
repeat nasal brushing.  
In 71 patients a conclusive multidisciplinary diagnosis was not made on first sampling due to 
insufficient tissue for light and/or electron microscopy. The immunofluorescence protocol 
required fewer ciliated cells and was able to produce a definitive result for 55% (39/71) of 
these cases. Two of these cases showed an absence of DNAH5 by immunofluorescence and 
this was supported subsequently by electron microscopy on a repeat biopsy as an outer 
dynein arm defect.  The remaining 37 samples, in which immunofluorescence testing was 
normal, were considered ‘PCD highly unlikely’ on second testing either by repeat nasal 
brushing (n=31) or by culturing the original sample at air liquid interface (n=6). Once a 
sufficiently ciliated sample had been acquired by repeat brushing or cell culture the high 
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speed video and electron microscopy as per the original protocol. None of these patients 
underwent genetic testing. 
 
Insufficient and inconclusive results were sometimes obtained by immunofluorescence when a 
multidisciplinary result was conclusive 
In 42 samples in which a multidisciplinary diagnosis was made there were not enough cells 
for immunofluorescence. In a further 32 samples in which a multidisciplinary diagnosis was 
made the immunofluorescence result for one or more antibody was inconclusive on more than 
one occasion. Sixty nine of these patients (represented by 71 samples) did not have PCD, 
however, two were diagnosed with PCD at the multidisciplinary meeting. One of these two 
patients yielded a sample which was insufficient for immunofluorescence, light microscopy 
and electron microscopy but was found to have a mutation in the CCNO gene 
(c.258_262dupGGCCC, p.Gln88Argfs*8). This patient was related to a previously 
genetically characterised family with reduced generation of multiple motile cilia [22]. The 
second patient with PCD had DNAH5, DNALI1 and GAS8 present, however, inconclusive 
results were obtained by immunofluorescence for RSPH4A on two separate slides and the 
other radial spoke head proteins RSPH1 and RSPH9 were absent. This patient had a circular 
beat pattern on light microscopy and a transposition /central pair complex defect detected by 
electron microscopy. These insufficient and inconclusive patients were excluded from the 
diagnostic accuracy analysis. In thirty five patients a diagnosis of ‘PCD positive’ or ‘PCD 
highly unlikely ’ could not be reached during the study period.  
 
We further investigated factors relating to insufficient and inconclusive immunofluorescent 
results. Both blood and mucus in the sample appeared to be confounding factors. In 63% of 
samples with inconclusive results by immunofluorescence viscous mucus was surrounding 
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the cilia on the high speed video light microscopy assessment compared to 46% of conclusive 
samples (p<0.05). In 25% of samples insufficient for immunofluorescence blood was seen in 
the sample compared to 8% in sufficient samples (p<0.01). The cause of this relationship is 
unknown. We hypothesise that increased blood could prevent cells from attaching to the 
slides thus reducing available sample for immunofluorescence. Alternatively an increase of 
blood in a sample could represent damaged mucosa denuded of cilia as a result of a recent 
infective or inflammatory process 
 
Samples were deemed insufficient or inconclusive if a result could not be obtained for one or 
more antibodies. Thirty percent were inconclusive or insufficient for just one antibody, 16% 
for two antibodies and 54% for three or more antibodies. Couriered and cultured samples 
showed similar results compared to nasal brushings taken on site. 
 
Time for results to be available and cost of investigation 
The effectiveness of immunofluorescence for diagnosis was compared to electron 
microscopy. The turnaround time, defined as time from the sample being taken to the results 
being reported was median 14 days (range 1 - 40) for immunofluorescence compared to 27 
days (range 9 - 61) for electron microscopy p<0.05.  Additionally a cost assessment exercise 
which included staff hours, equipment running costs and consumables showed that the cost 
per sample was $187 for immunofluorescence and $1452 for electron microscopy.  The 
assessment did not include the purchase and set up of equipment required or brushes for 
obtaining cells, as surplus cells from video microscopy are used for both techniques. 
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DISCUSSION 
Using immunofluorescence all cilia structural defects were correctly identified in an initial 
discovery cohort of patients with a known electron microscopy based ultrastructural diagnosis 
of PCD.  In a cohort subsequently tested for diagnostic accuracy consisting of 386 
consecutively referred cases immunofluorescence successfully identified 22 of 25 patients 
with a multidisciplinary diagnosis of PCD and 252 of 252 in whom the diagnosis was 
considered highly unlikely. The  accuracy of immunofluorescence was the same as that of 
electron microscopy. Immunofluorescence failed to identify 12% PCD cases in the present 
study, and may well miss more cases in populations with a different genetic makeup, and is 
therefore not suitable for use as a stand-alone test. This report does however provide strong 
evidence for introducing this test into clinical practice as part of the diagnostic 
armamentarium for PCD. 
 
The main strength of the immunofluorescence technique is the cost reduction and improved 
turnaround time relative to electron microscopy to confirm a diagnosis of PCD.  The cost of 
the test and the basic equipment and the simplicity of the test may allow improved 
accessibility to a wider population of patients. The immunofluorescence technique also works 
on small samples where there are too few cells to process for electron microscopy analysis. In 
the diagnostic cohort an additional 34 cases could have been diagnosed with the inclusion of 
immunofluorescence before electron microscopy in the diagnostic pathway. 
 
The strengths of this study include that it has been conducted in the UK clinical setting which 
follows a nationally audited and standardized algorithm for PCD diagnosis giving a realistic 
indication of how this test performs. Other strengths include the use of discovery and 
validation cohorts, with large numbers in this latter group in particular. 
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The foundation for pursuing this study, and an acknowledged problem in the field of PCD 
diagnostics, is the lack of gold standard for the diagnosis of PCD.  It is difficult to exclude a 
diagnosis of PCD due to poor sensitivity of electron microscopy and genetic testing and the 
poor specificity of nasal nitric oxide [15] Despite use of a multidisciplinary diagnosis to 
maximize diagnostic capability fifteen patients had an indeterminate diagnosis (a situation 
also seen in cystic fibrosis, for example). Our approach to ruling in or ruling out a diagnosis 
of PCD is certainly not perfect.  There are multiple variables that could lead to false-
negatives, including: 1) The lack of standardized clinical phenotyping, whereby diagnostic 
decisions are made by a monthly multi-disciplinary meeting (an approach which, however, is 
used in interstitial lung disease for example [16]), using clinical judgment.  There are two 
recently  published approaches to define specific criteria for a clinical phenotype that have 
significant predictive power for a subject having PCD which could be used in future studies 
[17,18] , although both also have imperfect sensitivity and specificity 2) lack of ciliary EM 
defects in ~30% of PCD patients [9], and many of these cannot be diagnosed by 
immunofluorescence; 3) the limitations of high-speed video-microscopy; 4) only a minority 
of patients (129 of 386) were tested by nasal nitric oxide, although normal nitric oxide does 
also not rule out PCD [10]; and, 5) there is limited genetic testing (16 of 386), and in any 
event, many PCD genes are currently unknown. Thus, it seems logical to conclude that an 
unknown number with indeterminate diagnosis will have PCD, and  exclusion of these cases 
from this study will have exaggerated the perceived accuracy of the immunofluorescence test. 
Nonetheless, our results suggest that immunofluorescence is a useful part of diagnostic 
testing for PCD.  
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Immunofluorescence was unsuccessful in a number of cases. These cases were excluded from 
the analysis. This resulted in a case with reduced generation of motile cilia (CCNO) being 
excluded from this study as there were insufficient cilia to perform the immunofluorescence 
test. Exclusion of unsuccessful immunofluorescence analysis is another factor which could 
lead to an over estimation of the testperformance. Test failure again highlights that 
immunofluorescence should not be used as a stand-alone test, as a number of patients would 
need further repeat investigations. We identified blood and mucus to be associated with failed 
testing and suggest further methodology improvements could focus on these factors. 
 
The major limitation of the immunofluorescence technique is that the antibodies used are 
directed to specific proteins of interest and therefore defects in unrelated proteins will be 
missed. The selected six antibody panel represents the major ultrastructural defects and end 
products of multiple gene defects, however three cases were still missed. The three cases 
missed in this study had biallelic mutations in DNAH11 and HYDIN. This is expected since 
previous publications have demonstrated the outer and inner dynein arms, nexin links and 
radial spokes are present in patients with these defects [14,19]. Normal ultrastructure cases 
such as these are also the most likely to be missed using our diagnostic protocol due to 
limited genetic studies.  Despite patients with DNAH11 mutations making up 8% of PCD 
positive patients in the validation cohort, which is in keeping with predicted numbers of 6-9% 
from genetic screening programs, it is possible that additional genetic testing may lead to the 
diagnosis of further PCD cases [19]. 
 
New reliable antibodies to DNAH11 have recently been reported and will benefit diagnosis 
and research in this area [20].  Antibodies to HYDIN proteins are commercially available 
however we have not been able to validate the use sufficiently for use in PCD diagnosis, nor 
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is there any report in the literature of the successful use of these antibodies to identify PCD. 
Furthermore, the cilium consists of over 200 proteins and patients with partial defects or 
missense mutations have been shown to have normal immunofluorescence results, it is 
therefore likely that other cases of PCD and reduced ciliation will be missed by the current 
immunofluorescence technique and the panel of antibodies will need to be increased in the 
future as the field of PCD genetics expands [20]. 
 
Given the similar diagnostic rate as electron microscopy we envisage that 
immunofluorescence could be useful where transmission electron microscopy equipment or 
expertise is not available. In specialist diagnostic centers where microscopy facilities are 
available the technique could be added to the diagnostic protocol to improve diagnostic 
success and reduce the number of electron microscopy tests required. Application of the 
immunofluorescence technique in this study was incorporated into our PCD diagnostic 
pathway following light microscopy assessment of cilia beat frequency and waveform.   
Firstly, a core panel of three antibodies was applied and then a second panel based on the 
primary panel and the light microscopy findings. This two-step protocol allows cost, time and 
tissue savings but introduces a selection bias. In this study three patients were diagnosed 
using the second panel by the GAS8 antibody. As absence of DNALI1 always co-existed 
with absence of GAS8 or DNAH5 we suggest DNALI1 might be substituted for GAS8 in the 
first panel. Recent data show that use of a RSPH9 antibody may detect a broader range of 
central pair complex defects than RSPH4A [21]. Therefore, GAS8, DNAH5 and RSPH9 
might be a more appropriate selection for the first panel. 
In conclusion immunofluorescence is a useful diagnostic test for PCD, reduces the need for 
repeat biopsies, and improves turnaround time without compromising diagnostic accuracy. 
We suggest it should be included in the routine PCD diagnostic pathway.  
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FIGURE LEGENDS 
Figure 1: Diagram of the ultrastructure of a motile cilium in transverse section. Labels 
indicate ultrastructural features targeted by immunofluorescence with corresponding 
antibodies (bold text). 
 
Figure 2; Workflow diagram indicating the pathway of patients from referral to diagnosis 
during the study period. Numbers in bold indicate the number of patients at each stage of the 
study (not the number of samples). Excluded groups are indicated in red.  
 
Figure 3: Example results in PCD and ‘PCD highly unlikely’ samples for three antibodies 
used in the immunofluorescence panel. The left column shows the cell nucleus in blue by 
DAPI, the next column shows presence of cilia on the cell in green by acetylated tubulin. The 
third column shows the protein of interest in red and the final column a merged image of the 
three channels. In the merged image yellow suggests co-localisation and presence of the 
protein of interest, green suggests absence of the protein of interest. The top images show 
DNALI1 (an inner dynein arm component), the middle images DNAH5 (an outer dynein arm 
component), and the bottom RSPH4A (a radial spoke head component) 
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TABLES 
Ultrastructural 
Defect 
Gene Immunofluorescence 
Outer dynein arm 
defect 
DNAH5 DNAH5 Absent 
DNAI1 
ARMC4 
CCDC114 
TXNDC3 
(NME8) 
DNAI2 
DNAL1 
CCDC151 
   
Inner and outer 
dynein arm defect 
C21orf59 DNAH5 Absent 
DNALI1 Absent ZYMND10 
CCDC103 
DNAFF2 
(KTU) 
DNAFF1 
(LRRC50) 
LRRC6 
DNAFF3 
(C19orf31) 
HEATR2 
DYX1C1 
SPAG1 
   
Central complex / 
transposition defect 
RSPH4A RSPH9, RSPH4A,RSPH1 
absent 
RSPH9 RSPH9 absent 
RSPH1 RSPH9, RSPH1 absent 
RSPH3 All present 
   
Microtubular 
disorganisation 
with loss of inner 
dynein arm 
CCDC39 DNALI1 Absent 
GAS 8 Absent CCDC40 
   
Microtubular 
disorganisation 
with present  inner 
dynein arms 
CCDC65 GAS 8 Absent 
CCDC164 
GAS8 
   
Normal ciliary 
ultrastructure 
HYDIN All present 
DNAH11 
OFD1 
RPGR 
   
Ciliary ‘aplasia’  CCNO All present  
DNAH5& LI1Absent 
 
MCIDAS 
Table 1: The major classes of ultrastructural defects seen in PCD and the gene associated 
with each defect (former gene name is shown in brackets). Column three shows the assumed 
coverage of the six antibodies investigated in this study over the known ultrastructural and 
gene defects. Absent = complete or partial absence from the axoneme  
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Table 2: Immunofluorescence antibody results from 35 patients with primary ciliary 
dyskinesia due to a known ultrastructural defect 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Diagnostic outcome table comparing immunofluorescence technique to the standard 
diagnostic approach in 271 patients referred to a national referral centre for investigation into 
symptoms suggestive of primary ciliary dyskinesia (PCD)
Electron 
microscopy defect 
 
Absent or 
mislocalised  
antibody 
 
Number of 
patients with 
PCD tested 
(total n=35) 
Outer dynein arm 
defect 
 
DNAH5 14 
Outer and inner 
dynein arm defect 
 
DNAH5   
DNALI1 
10 
Inner dynein arm 
and microtubular 
disorganisation 
defect 
 
DNALI1  GAS8 7 
Transposition defect 
/ central pair 
absence 
RSPH4A 
RSPH9 RSPH1 
4 
Standard diagnosis 
PCD 
positive 
PCD 
negative 
Im
m
u
n
o
fl
u
o
re
s
c
e
n
c
e
 
d
ia
g
n
o
s
is
 PCD positive 22 0 
PCD negative 3 252 
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Multidisciplinary 
diagnosis  Electron microscopy Immunofluorescence  
 n  
Panel 1 Panel 2 
DNAH5  DNALI1 RSPH4A   GAS8 RSPH9 RSPH1 
Normal 
n= 208 208 
Normal ultrastructure 
 
97% both dynein arms present (+/- 7%) 
89% normal microtubular arrangement (+/-
6%) 
present present present ND ND ND 
   
 
 
  
  
PCD 
n= 25 
  
8 IDA and ODA defect absent absent present present ND ND 
 8 ODA defect absent present present ND ND ND 
   2 IDA and MTD defect present absent present absent ND ND 
   1 Transposition defect present present absent present absent absent 
   3 MTD defect present present present absent present present 
   3 Normal ultrastructure present present present present present present 
Table 4: Comparison of results from, electron microscopy and immunofluorescence testing of nasal brushings from patients referred due to clinical 
symptoms suggestive of primary ciliary dyskinesia. Results from all diagnostic tests are shown in supplementary table 1 
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Figure 1: Diagram of the ultrastructure of a motile cilium in transverse section. Labels indicate 
ultrastructural features targeted by immunofluorescence with corresponding antibodies (bold text).  
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Figure 2; Workflow diagram indicating the pathway of patients from referral to diagnosis during the study 
period. Numbers in bold indicate the number of patients at each stage of the study (not the number of 
samples). Excluded groups are indicated in red.  
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Figure 3: Example results in PCD and ‘PCD highly unlikely’ samples for three antibodies used in the 
immunofluorescence panel. The left column shows the cell nucleus in blue by DAPI, the next column shows 
presence of cilia on the cell in green by acetylated tubulin. The third column shows the protein of interest in 
red and the final column a merged image of the three channels. In the merged image yellow suggests co-
localisation and presence of the protein of interest, green suggests absence of the protein of interest. The 
top images show DNALI1 (an inner dynein arm component), the middle images DNAH5 (an outer dynein 
arm component), and the bottom RSPH4A (a radial spoke head component)  
 
346x559mm (72 x 72 DPI)  
 
 
Page 30 of 39 AJRCCM Articles in Press. Published on 15-February-2017 as 10.1164/rccm.201607-1351OC 
 Copyright © 2017 by the American Thoracic Society 
Supplementary methods 
Subjects 
Sequential nasal brushings were analysed from 386 patients referred to the paediatric 
department at the Royal Brompton Hospital for PCD diagnosis.  Referrals were due to 
symptoms suggestive of PCD such as situs inversus, neonatal respiratory distress, 
bronchiectasis, recurrent chest infections, rhinosinusitis and/or otitis media. The 
prevalence of symptoms for which patients were referred are shown in supplementary 
table one.  
 
Inclusion criteria: Consecutively referred patients undergoing a nasal brushing at a 
national diagnostic centre due to symptoms suggestive of PCD.  
 
Exclusion criteria: Patients who did not wish for their data or surplus samples to be 
used for research or could not consent because the biopsy was taken elsewhere and 
couriered to the Royal Brompton Hospital (n=22). Patients who were referred to the 
service but based on nasal nitric oxide and atypical clinical features further PCD 
testing was not required (not biopsied n=185).  
 
 
 
 
Diagnosis of PCD 
All patients underwent the clinical PCD diagnostic protocol according to standard 
operating procedures at the Royal Brompton Hospital as follows: 
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1. Assessment of clinical history for factors suggestive of PCD (n= 378/386; 8 
external samples had a limited clinical history).  
Clinical suspicion was considered strong if more than two of the following 
factors were present and were unexplained by a differential diagnosis such as 
cystic fibrosis or immune deficiency: Neonatal distress in a term infant, 
chronic wet cough and/or  chronic nasal symptoms since birth, bronchiectasis, 
situs abnormalities, persistent otitis media, otorrhoea or hearing impairment. 
Otherwise clinical suspicion was considered modest. 
 
2. Nasal Nitric Oxide measurement – In children over the age of 4yrs able to 
hold their breath for more than 15 seconds. Four readings from both nostrils 
taken during a breath hold manoeuvre using a chemiluminescent analyser 
LR2000 (Logan Research, Rochester, Kent, UK) [9] (n= 129/386). Values of 
<77nl/min were considered low. 
 
3. High speed video microscopy for cilia beat frequency and ciliary beat pattern 
measured at 37ºC using a 100x oil objective [10] (n=386/386). If ciliary beat 
frequency was <8Hz, >16 Hz  or the sample contained any area of dyskinesia the 
sample proceeded to electron microscopy. If ten ciliated strips of more than 10 
cells could not be observed the sample was considered inadequate and sample 
culture was requested. Where culture failed a repeat sample was requested. If 10 
strips on 10 cells had completely normal beat pattern and beat frequency the 
sample was processed for electron microscopy but not analysed (blocked and 
stored as normal). 
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4. Quantitative transmission electron microscopy of ciliary ultrastructure [11] 
(n=208/386). Electron microscopy was considered normal if >90% of at least 100 
cilia from different sample areas showed normal ultrastructure. If less than 100 
cross sections could be counted, the sample was considered inadequate and a 
repeat sample or sample culture was requested. Hallmark defects of PCD were 
considered to be outer dynein arm defect, inner and outer dynein arm defect, 
central complex defect, Microtubular disorganisation +/- inner dynein arm defect 
5. Air liquid interface culture of unhealthy or inadequate samples with repeat light 
and electron microscopy [12] (n=115/386) 
6. Genotyping from blood samples in patients with likely PCD based on other 
investigations as part of our genetic research program (n=16/386) 
 
This protocol is standardised and regularly audited across the three UK diagnostic 
PCD centres and is in accordance with European diagnostic guidelines [5].  
 
Repeat samples were taken following treatment of any upper respiratory tract 
symptoms when the initial sample was deemed  inadequate. Repeat samples were 
analysed by light microscopy and electron microscopy in the same way as a new case. 
 
A diagnosis of PCD was made following review of all clinical and laboratory findings 
in a monthly multidisciplinary meeting (MDT) led by a consultant in paediatric 
respiratory medicine with expert knowledge of PCD. Decision making was based 
around evidence in recent European Diagnostic Guidelines for the diagnosis of PCD 
[13]. 
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 PCD was diagnosed if the following criteria were met:  
1. Clinical symptoms consistent with PCD and if measured low nasal nitric oxide 
levels (<77nl/min).  
2. Abnormal ciliary beat pattern known to be associated with PCD on high speed 
video microscopy  
3. Abnormal cilia ultrastructure demonstrated by transmission electron 
microscopy and/or  unequivocal disease-causing bi-allelic gene mutations 
recognised to cause PCD. 
 
Patients were considered to be very unlikely to have PCD where there was a: 
1. Low or modest clinical suspicion  
2. Completely normal ciliary beat pattern OR normal ciliary beat pattern 
present in the majority of the sample and normal electron microscopy.  
Of note, 15 patients in this group had a nasal nitric oxide <77nl/min. In all cases the 
clinical phenotype was not typical of PCD and this was attributed to another cause of 
nasal obstruction or poor technique.  
 
In thirty five patients a diagnosis of ‘PCD positive’ or ‘PCD highly unlikely’ could 
not be reached during the study period. Twenty had an insufficient sample from their 
first or second nasal brushing and have not yet returned for follow up. Fifteen 
remained inconclusive despite repeating the investigations. These subjects had 
moderate or high clinical suspicion and an abnormal result on one or more test but did 
not have a hallmark defect by electron microscopy or  an unequivocal gene mutation 
(where tested). These subjects were excluded from the analysis. None had a beat 
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pattern in keeping with a known defect (e.g none were completely immotile or with 
the hyperfrequent beat pattern associated with DNAH11) 
 
 
Experimental methods 
Nasal brushings were obtained using a modified 3mm cytology brush [13] and the 
sample applied to the centre of clean uncoated circle slide (Thermo scientific, UK). 
Six slides were prepared per patient and allowed to dry overnight. All slides were 
assigned a unique 7-digit code to preserve anonymity and blind the observer to other 
clinical details of the case. Slides were stored unfixed at -20ºC until immunolabelled. 
An immunolabelling run was conducted weekly and slides visualised within 48 hours. 
 
After slide preparation for immunofluorescence the remainder of the sample was used 
for transmission electron microscopy. The impact of splitting the sample on the 
electron microscopy result was audited regularly and no detrimental effect was found.  
Conversely there was a slight decrease in the number of insufficient samples 
compared to the two years prior to the study (21% during study, 37% prior to study). 
2013-2015, 37% 2009-2011). 2012 is excluded from this data as samples were used 
for IF during protocol testing in the run up to the study. 
 
A method adapted from Fliegauf et al was used for immunofluorescence [4]. Cells 
were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) at  pH 7.4  for 
10 minutes. A combined blocking and permeablisation step using 0.1% Triton in PBS 
(Triton X-100, Sigma Life Sciences, UK) with 5% milk powder solution was 
conducted for an hour. This was followed by the addition of primary antibodies for 2 
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hours and then secondary antibodies for a further 30 minutes. All slides were double 
labelled with acetylated alpha tubulin (T7451, Sigma Aldrich, dilution1:1000) in 
order to visualise the cilia. Antibodies of interest were DNAH5 (HPA037470, dilution 
1:1000, Sigma Aldrich), DNALI1 (HPA053129, dilution 1:100, Sigma Aldrich), 
GAS8  (HPA041311, dilution 1:50 Sigma Aldrich), RSPH4A (HPA031196, dilution 
1:500, Sigma Aldrich), RSPH9 (HPA031703, Sigma Aldrich, dilution 1:100) or 
RSPH1(HPA017382, Sigma Aldrich , 1:100). Secondary antibodies used were goat 
anti-mouse IgG and a goat anti-rabbit IgG (Alexa Fluor 488, A11001 and Alexa Fluor 
594, A11012, respectively. Life Technologies, UK). The two secondary antibodies 
were added simultaneously at 1:1000 dilution in PBS. Thorough washing with PBS 
was conducted between each step. 
 
Slides were cover-slipped in mountant containing DAPI to preserve the preparation 
and allow visualisation of the cell nucleus (ProLong Gold  P36931, Invitrogen Life 
Technologies, UK). Preparations were viewed and photographed using a Zeiss 
Axioskop fluorescent microscope with Axiocam HR camera. Slides were scanned for 
ciliated cells using a x40 oil immersion objective to identify 488nm labelled 
acetylated tubulin. In each ciliated cell found, the co-localised 594nm labelled ciliary 
protein of interest was assessed in a second channel. If there was visual co-
localisation of the antibody label with acetylated tubulin the target protein was 
considered present. If more than seven of ten ciliated cells were clearly labelled the 
sample was considered normal for that protein.  PCD was defined as at least ten of ten 
ciliated cells with absent or partial staining of the target protein and was repeated on a 
duplicate slide for confirmation.  
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When findings were variable within the sample or the protein of interest was present 
but difficult to distinguish above the background fluorescence the sample was deemed 
inconclusive.  The sample was deemed insufficient in the absence of 10 ciliated cells.  
 
The discovery cohort showed that diagnostic confidence remained 100% if 100, 75, 
50, 25, 10 cells were analysed. It was not deemed appropriate to use less than 10 cells 
for diagnostic purposes. 
 
Insufficient and inconclusive slides were repeated. If the second assessment was 
normal the second assessment was included in results (n=71). This is standard 
practice and repeat assessments are made for all other PCD diagnostic tests if the first 
result is inconclusive. 
 
Antibodies were used in a two step protocol. All nasal brushings were assessed for 
DNAH5 (outer dynein arm heavy chain), DNALI1 (inner dynein arm light 
intermediate chain) and RSPH4A (radial spoke head). A second round of 
immunofluorescent staining was used in selected cases. GAS8 (nexin - dynein 
regulatory complex component) was used where light microscopy described the 
majority of cilia having a stiff or staggered beat or where DNALI1 was absent (n=54). 
RSPH9 or RSPH1 (alternative radial spoke head proteins) were used when light 
microscopy described a circular or semi circular beat pattern or RSPH4A was absent 
or inconclusive (n=17) 
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Data analysis 
The workflow is shown in figure 2. Patients with a diagnosis of ‘PCD- positive’ or 
‘PCD-highly unlikely’ were included (n=277). Those patients where the diagnosis 
was inconclusive at the end of the study period were not included (n=35 patients). 
Those patients where immunofluorescence results were deemed ‘insufficient’ or 
‘inconclusive’ were also excluded from these calculations (71 patients) 
 
Immunofluorescence result delivery was assessed by time taken to return results, cost 
of test and procedure failure rate. These factors were compared to electron 
microscopy as the main confirmatory investigation of structural defect in the cilium.  
 
Cost analysis 
The cost analysis for immunofluorescence includes staff salary (0.3WTE per week- 1 
day for the processing and half a day for analysis), equipment running costs 
(fluorescent microscope annual service and bulb replacement) and consumables 
(primary antibodies, secondary antibodies, slides, coverslips and other reagents). This 
is based on a throughput of ~200 samples per year.  
 
The costs analysis for electron microscopy includes (1.0 WTE per week – 3 days for 
processing and sectioning and two days for analysis). Equipment running costs 
(transmission electron microscope and microtome service) and consumables.  This is 
based on a throughput of ~100 samples per year.  
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Neither analysis include initial set up costs such as purchase of equipment. The 
brushes used for obtaining the cells are not included in either calculation as surplus 
sample from high speed video microscopy is used. 
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